Ivernia to buy rest of Magellan lead mine

Ivernia (IVW-T) plans to sell $65-82.5 million worth of newly minted shares to buy the 49% interest in the Magellan lead mine it does not already own. The mine is 740 km northeast of Perth, Australia.

The sale would consist of 33-42 million shares, based on the company’s closing share price of $1.97 in Toronto on April 4, the day of the announcement. Ivernia currently has 68.1 million shares outstanding.

Ivernia can acquire the 49% stake, currently held by Sentient Global Resources Fund, by paying $55 million in cash and issuing 16.6 million shares. Ivernia is also on the hook for $12.5 million in cash, or 6.9 million shares (or any proportionate combination thereof), as long as Sentient does not end up with more than 19.9% of Ivernia’s outstanding shares.

Also under the deal, Ivernia acquires the vendor’s share of US$39.8 million worth of development loans.

At last count, proven and probable reserves at Magellan amounted to 16.2 million tonnes grading 6.2% lead, based on a cutoff grade of 3% lead. There were also 13 million tonnes at 4.3% lead in the inferred category.

Ivernia recently launched a A$1.2-million drilling program designed to upgrade inferred resources to the indicated category. New reserve and resource estimates are expected by mid-year.

In 2006, Magellan is expected to process 1.4 million tonnes of ore, from which will be extracted 100,000 tonnes of lead-in-concentrate.

The project comprises the shallow Cano and Magellan open pits. The Cano deposit will be mined first, as its ore is readily accessible.

Initially, lead-in-concentrate will be shipped from the concentrator to offshore smelters. During the second phase, in 2006, a planned refinery will produce a 99.95% soft lead metal. Lead will be recovered from the deposits’ clean, oxidized ore by means of crushing, grinding, flotation and filtration.

The share offering has yet to be approved by regulators.

Print

Be the first to comment on "Ivernia to buy rest of Magellan lead mine"

Leave a comment

Your email address will not be published.


*


By continuing to browse you agree to our use of cookies. To learn more, click more information

Dear user, please be aware that we use cookies to help users navigate our website content and to help us understand how we can improve the user experience. If you have ideas for how we can improve our services, we’d love to hear from you. Click here to email us. By continuing to browse you agree to our use of cookies. Please see our Privacy & Cookie Usage Policy to learn more.

Close